Continuous Subcutaneous Insulin Infusion Market Size & Growth Forecast 2026–2035, By Segments (Patient Type, Product, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Continuous Subcutaneous Insulin Infusion Market size was over USD 717.25 Million in 2025 and is likely to grow at a 9.1% CAGR between 2026 and 2035, exceeding USD 1.71 Billion by 2035. The industry revenue for 2026 is calculated at USD 774.07 million.
Get more details on this report
Request Free Sample ReportContinuous Subcutaneous Insulin Infusion Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 41.55% share in 2025, supported by established diabetes care pathways, widespread insulin pump adoption, and integrated patient monitoring and follow-up across specialist clinics.
- Asia Pacific is projected to grow at a 10.28% CAGR as access to diabetes care improves, insulin pump availability expands, and more patients adopt technology-enabled insulin delivery.
Segment Momentum
- Diabetes Type 1 leads with a 78% share due to continuous insulin dependence and strong alignment with pump-based therapy for precise basal and bolus dosing in routine management.
- Patch Pumps are growing fastest due to demand for discreet, wearable, and tubing-free designs that improve convenience, mobility, and ease of use compared with traditional insulin delivery systems.
Market Expansion Drivers
- Rising global diabetes prevalence increasing demand for advanced insulin delivery systems.
- Integration of AI-enabled insulin pumps and CGM systems improving glycemic control.
- Expanding geriatric population driving adoption of automated diabetes management technologies.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key companies in the continuous subcutaneous insulin infusion market include Medtronic plc (Ireland), Insulet Corporation (United States), Roche Holding AG (Switzerland), Ypsomed Holding AG (Switzerland), B. Braun SE (Germany), CeQur SA (Switzerland), Tandem Diabetes Care, Inc. (United States), SOOIL Development Co., Ltd. (South Korea).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As diabetes diagnoses continue to expand globally, clinicians and patients are placing greater emphasis on delivery methods that improve dosing precision, reduce injection burden, and support tighter glucose management over long treatment periods. This is directing more attention toward pump-based therapy in the continuous subcutaneous insulin infusion market, particularly for patients whose daily insulin needs are difficult to manage through multiple daily injections alone. The rise in insulin-dependent and intensively managed diabetes cases is also influencing provider prescribing behavior and payer evaluation, reinforcing demand for systems that can help reduce glycemic variability and support more consistent self-management.
Integration of AI-enabled insulin pumps and CGM systems improving glycemic control
The combination of AI-enabled insulin pumps with continuous glucose monitoring is reshaping product value in the continuous subcutaneous insulin infusion market by shifting devices from insulin delivery tools to adaptive management platforms. Real-time glucose data linked to algorithm-driven dosing adjustments helps reduce manual decision-making and supports more responsive insulin administration, which is influencing market adoption among both patients seeking ease of use and clinicians focused on measurable control outcomes. This integration is also strengthening replacement demand as users move toward interoperable systems that offer automation, data visibility, and tighter alignment with personalized diabetes care.
Expanding geriatric population driving adoption of automated diabetes management technologies
An expanding older population is increasing the need for diabetes technologies that reduce the complexity of daily insulin management, especially where vision, dexterity, cognition, or caregiver dependence affect treatment adherence. In the continuous subcutaneous insulin infusion market, this is encouraging market growth for automated and user-friendly pump systems that can simplify dosing routines and lower the burden of frequent manual adjustments. Healthcare providers and families are more likely to consider technologies that improve consistency and reduce the risk of administration errors, which is increasing market presence among elderly patients requiring long-term insulin therapy.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global diabetes prevalence increasing demand for advanced insulin delivery systems | 2.50% | High | North America, Asia Pacific | High | Near Term |
| Integration of AI-enabled insulin pumps and CGM systems improving glycemic control | 2.00% | High | North America, Europe | High | Mid Term |
| Expanding geriatric population driving adoption of automated diabetes management technologies | 1.50% | High | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 41.55% share of the continuous subcutaneous insulin infusion market in 2025, supported by broad access to insulin pump technologies, established diabetes management pathways, and strong familiarity with device-based insulin delivery among providers and patients. The region’s leadership is aided by routine use of advanced diabetes care across specialist clinics, higher uptake of connected infusion systems, and a treatment environment where training, monitoring, and follow-up are already integrated into care delivery. These practical conditions help sustain steady device adoption and replacement demand across the installed user base.
Asia Pacific is projected to expand at a 10.28% CAGR over the forecast period, with growth in the continuous subcutaneous insulin infusion market being propelled by widening access to diabetes care and increasing adoption of modern insulin delivery solutions across major patient populations. Momentum is being shaped by rising diagnosis and treatment activity, improving availability of infusion devices in developing healthcare systems, and stronger acceptance of technology-enabled diabetes management in urban care settings. As more patients move from conventional insulin administration toward pump-based therapy, regional demand is accelerating through real-world adoption rather than niche use.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Structured diabetes care systemsIn Germany, continuous subcutaneous insulin infusion market activity is shaped by structured chronic disease management programs. Germany emphasizes clinically guided insulin pump adoption, with demand supported by reimbursement-backed healthcare pathways and strong physician-led diabetes care protocols.
France 🇫🇷
Reimbursement-supported adoptionIn France, continuous subcutaneous insulin infusion market activity is influenced by reimbursement-driven access to advanced diabetes therapies. France prioritizes clinically validated insulin pump systems within public healthcare pathways for long-term disease management.
Italy 🇮🇹
Specialist-led insulin therapyIn Italy, continuous subcutaneous insulin infusion market demand is shaped by specialist-driven diabetes care practices. Italy focuses on gradual adoption of insulin pump technologies supported by hospital endocrinology departments and patient-centered chronic care models.
Japan 🇯🇵
Precision diabetes managementIn Japan, continuous subcutaneous insulin infusion market demand reflects precision-focused diabetes care in an aging population. Japan prioritizes advanced insulin delivery systems that support tight glycemic control and long-term disease stability under specialist supervision.
South Korea 🇰🇷
Digital diabetes monitoring growthIn South Korea, continuous subcutaneous insulin infusion market demand is supported by expanding digital health adoption and improved diabetes diagnostics. South Korea emphasizes connected insulin delivery systems integrated with mobile monitoring and hospital-based care networks.
United States 🇺🇸
Diabetes tech adoption leadershipIn the U.S., continuous subcutaneous insulin infusion market demand is driven by strong adoption of advanced diabetes management technologies. The U.S. prioritizes insulin pump integration with digital monitoring systems, with uptake supported by specialist endocrinology care and reimbursement structures enabling long-term chronic disease management.
Segment Leadership and Growth Trends
Continuous Subcutaneous Insulin Infusion Market Share (%), Patient Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the continuous subcutaneous insulin infusion market, Diabetes Type 1 held the strongest position in 2025 with a 78% share. This dominance is sustained by the routine and intensive nature of insulin dependence in Type 1 management, where continuous insulin delivery is closely aligned with daily treatment requirements. The segment’s leadership reflects the established fit between pump-based therapy and the need for precise basal and bolus dosing, which keeps Diabetes Type 1 at the center of device adoption in the market.
Diabetes Type 2 is emerging as the fastest-growing patient type in the continuous subcutaneous insulin infusion market as treatment approaches broaden beyond the traditional core user base. Growth is being backed by rising adoption among patients whose insulin needs become more complex over time and require better day-to-day dosing control than conventional delivery methods may offer. Compared with Diabetes Type 1, this segment is expanding from a lower installed base, giving it stronger growth momentum as pump therapy becomes more relevant in advanced Type 2 insulin management.
Product Segment Analysis: Tethered Pumps (Largest Segment) vs Patch Pumps (Fastest-Growing Segment)
Tethered Pumps accounted for the largest position in the continuous subcutaneous insulin infusion market in 2025, capturing a 74.4% share. Their continued leadership is tied to long-standing clinical familiarity and broad usage across established insulin pump users, particularly where consistent delivery performance and proven therapy management workflows remain central to adoption. In the continuous subcutaneous insulin infusion market, this installed-base advantage helps Tethered Pumps maintain their lead over newer product formats.
Patch Pumps are the fastest-growing product segment in the continuous subcutaneous insulin infusion market, encouraged by increasing demand for simpler and less obtrusive insulin delivery options. Their momentum comes from practical user preference for more discreet, wearable designs that reduce the burden associated with conventional tubing-based systems. Relative to Tethered Pumps, Patch Pumps are seeing wider adoption because they better match evolving expectations around convenience, ease of use, and everyday mobility.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Patient Type | Diabetes Type 1, Diabetes Type 2 | Diabetes Type 1 | Diabetes Type 2 |
| Product | Patch Pumps, Tethered Pumps | Tethered Pumps | Patch Pumps |
| End Use | Hospitals & Clinics, Homecare, Laboratories | Hospitals & Clinics | Homecare |
Competitive Landscape and Market Positioning
1. Medtronic plc (Ireland)
2. Insulet Corporation (United States)
3. Roche Holding AG (Switzerland)
4. Ypsomed Holding AG (Switzerland)
5. B. Braun SE (Germany)
6. CeQur SA (Switzerland)
7. Tandem Diabetes Care Inc. (United States)
8. SOOIL Development Co. Ltd. (South Korea)
The continuous subcutaneous insulin infusion market is evolving rapidly with advancements in automated insulin delivery systems and connected diabetes management technologies. Manufacturers are emphasizing user-friendly wearable devices, AI-supported glucose monitoring integration, and personalized insulin delivery algorithms to improve treatment outcomes. Rising adoption of remote healthcare solutions is also strengthening innovation in diabetes care platforms.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Abbott & Medtronic | Aug-24 | The companies announced a global partnership to integrate Abbott’s FreeStyle Libre CGM sensor technology with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems. This collaboration aims to provide a seamless, integrated diabetes management solution, pairing Abbott's sensing technology with Medtronic's advanced insulin delivery algorithms. |
| F. Hoffmann-La Roche Ltd | Jul-24 | The company received CE Mark certification for the Accu-Chek SmartGuide, an AI-enabled continuous glucose monitoring (CGM) system. Designed for patients 18 and older with type 1 or type 2 diabetes on flexible insulin therapy, the system provides real-time glucose readings and predictive alerts to help users manage their condition and prevent hypoglycemia. |
| Medtronic | Sep-23 | The company received CE Mark approval for its Simplera continuous glucose monitor (CGM). This all-in-one, disposable device features a simple, two-step insertion process and a 50% smaller profile compared to previous sensors, significantly enhancing convenience and reducing the environmental impact of diabetes monitoring equipment. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Continuous Subcutaneous Insulin Infusion Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Continuous Subcutaneous Insulin Infusion Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the continuous subcutaneous insulin infusion market?
What is the expected industry size of continuous subcutaneous insulin infusion by 2035?
How is rising diabetes prevalence influencing the shift toward pump-based insulin delivery in the continuous subcutaneous insulin infusion market?
How are AI-enabled pump-CGM integration and aging patient needs shaping adoption patterns in insulin infusion systems?
Why does Diabetes Type 1 dominate the continuous insulin infusion market?
Why are Patch Pumps the fastest-growing product segment in insulin infusion systems?
What makes North America the largest continuous subcutaneous insulin infusion market?
Why is Asia Pacific experiencing rapid growth in the continuous subcutaneous insulin infusion market?
Who holds a significant market share in the continuous subcutaneous insulin infusion landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization